Combinations involving checkpoint therapies are starting to be used as the standard of care in certain metastatic cancer types, such as Merck’s Keytruda (pembrolizumab) with chemotherapy in advanced squamous non-small cell lung cancer, according to GlobalData, a leading data and analytics company.
Combinations involving checkpoint therapies are starting to be used as the standard of care in certain metastatic cancer types, such as Merck’s Keytruda (pembrolizumab) with chemotherapy in advanced squamous non-small cell lung cancer, according to GlobalData, a leading data and analytics company.
Among the six approved checkpoint inhibitors—Keytruda, Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), AstraZeneca’s Imfinzi (durvalumab), Roche’s Tecentriq (atezolizumab), and Merck KGaA/Pfizer’s Bavencio (avelumab)— the majority of ongoing Phase I to Phase III clinical trials involve a combination regimen.
Francesca Blum, MSci, UK Director of Oncology at GlobalData, comments, “This is a reflection of the need, in many cancer types, to improve upon the efficacy achieved with checkpoint agents as monotherapies, and to better serve the substantial number of patients who do not respond to checkpoint agents alone. Although the increased cost of adding other treatment modalities to already expensive checkpoint inhibitors could present a significant barrier to market access, the trend for combination trials shows no sign of slowing at present.”
All six of the marketed checkpoint modulators are being studied in trials in combination with several other types of therapy: immuno-oncology (IO) agents, non-IO targeted agents (defined by GlobalData as small molecules or biologics with a non-immune-related target), chemotherapy, radiotherapy, or chemoradiotherapy.
Blum adds: “The most common types of combination partners for all six approved checkpoint inhibitors are either non-IO targeted agents or other IO agents, with Opdivo, Imfinzi and Yervoy having notably large numbers of ongoing studies with other IO agents.
“No single type of combination, including checkpoint agents, has been proven so far to be a superior option across cancer indications, suggesting broad opportunities for developers to test their checkpoint assets in multiple indications and combinations. Indeed, among the 115 checkpoint inhibitors currently being investigated in the clinic, differentiation from the six approved agents will be key to their success, and combination strategies may be the best way to achieve this.”
ENDS
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
Email: pr@globaldata.com
For expert analysis on developments in your industry, please connect with us on:
GlobalData.com | Facebook | LinkedIn | Twitter
About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.